Clinical Trials for Amicus Therapeutics

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Amicus Therapeutics

Clinical Trials (8)

NCT06904261
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
PHASE3Recruiting
8 participants
Started: Oct 31, 2025 · Completed: Dec 31, 2028
1 condition1 sponsor7 locations
NCT06906367
A Study of Patients With Fabry Disease (US Specific)
N/ANot yet recruiting
450 participants
Started: Oct 31, 2025 · Completed: Jun 30, 2032
1 condition1 sponsor4 locations
NCT04252066
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
N/ARecruiting
20 participants
Started: Mar 18, 2025 · Completed: Feb 28, 2030
1 condition1 sponsor1 location
NCT06121011
A Global Prospective Observational Registry of Patients With Pompe Disease
N/ARecruiting
500 participants
Started: Feb 16, 2024 · Completed: Dec 20, 2034
1 condition1 sponsor40 locations
NCT06303466
Real World Evidence Study of Danish Fabry Patients
N/AActive, not recruiting
115 participants
Started: Aug 1, 2023 · Completed: Dec 31, 2024
1 condition3 sponsors1 location
NCT04808505
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
PHASE3Recruiting
36 participants
Started: Jul 18, 2023 · Completed: Apr 30, 2027
1 condition1 sponsor16 locations
NCT04020055
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
PHASE3Recruiting
14 participants
Started: Oct 31, 2022 · Completed: Dec 31, 2026
1 condition1 sponsor15 locations
NCT03911505
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
PHASE3Recruiting
22 participants
Started: Feb 13, 2020 · Completed: Jun 30, 2026
1 condition1 sponsor23 locations